Genetic Predictors of Adverse Radiotherapy Effects (Gene-PARE)

Request Access

Demographics (1)

age.at.Rx - Subject age at time of radiotherapy (phv00202681.v1.p1)

Disease Events (8)

diabetes - Diabetes status at the time of radiotherapy (phv00202692.v1.p1)
ED - Erectile dysfunction (phv00202672.v1.p1)
gleason.score - Gleason score of prostate tumor (phv00202685.v1.p1)
hypertension - Hypertension status at the time of radiotherapy (phv00202693.v1.p1)
initial.PSA - Blood concentration of prostate specific antigen (PSA) (phv00202686.v1.p1)
PreRT.AUASS - Pre-radiotherapy AUASS score (phv00202680.v1.p1)
proctitis - Proctitis/rectal bleeding (phv00202673.v1.p1)
stage - Prostate tumor stage (phv00202684.v1.p1)

General Health (2)

prior.TURP - Transurethral resection of the prostate prior to radiotherapy (phv00202679.v1.p1)
prostatectomy - Radical prostatectomy prior to radiotherapy (phv00202687.v1.p1)

Imaging (1)

CT.Volume - Prostate volume on CT scan prior to radiotherapy (phv00202688.v1.p1)

Medications (2)

alpha.blockers - Use of alpha-blocker drugs during treatment or follow-up (phv00202694.v1.p1)
hormones - Anti-androgen therapy given before, during and/or after radiotherapy (phv00202682.v1.p1)

Race and Ethnicity (1)

race - Self-reported race/ethnicity of participant (phv00202678.v1.p1)

Substance Use (1)

smoker - Smoking status at the time of radiotherapy (phv00202691.v1.p1)

Other (23)

ANALYTE_TYPE - Analyte type (phv00202697.v1.p1)
BODY_SITE - Body site where sample was collected (phv00202696.v1.p1)
CONSENT - Consent group as determined by DAC (phv00202663.v1.p1)
EBRT.Dose - Radiation dose delivered from external beam radiotherapy (phv00202690.v1.p1)
GENOTYPING_CENTER - Name of the center which conducted genotyping (phv00202700.v1.p1)
HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00202698.v1.p1)
IPSS.delta.y1 - Change in AUASS score from baseline recorded between 1 and 2 years following radiotherapy (phv00202674.v1.p1)
IPSS.delta.y2 - Change in AUASS score from baseline recorded between 2 and 3 years following radiotherapy (phv00202675.v1.p1)
IPSS.delta.y3 - Change in AUASS score from baseline recorded between 3 and 4 years following radiotherapy (phv00202676.v1.p1)
IPSS.delta.y4 - Change in AUASS score from baseline recorded between 4 and 5 years following radiotherapy (phv00202677.v1.p1)
IS_TUMOR - Tumor status (phv00202699.v1.p1)
SAMPLE_ID - De-identified sample ID (phv00202695.v1.p1)
SAMPLE_ID - Sample ID (phv00202667.v1.p1)
SAMPLE_SOURCE - Source repository where samples originate (phv00202668.v1.p1)
SAMPLE_USE - Sample Use (phv00202670.v1.p1)
SOURCE_SAMPLE_ID - Sample ID used in the Source Repository (phv00202669.v1.p1)
SOURCE_SUBJECT_ID - Subject ID used in the Source Repository (phv00202665.v1.p1)
SUBJECT_ID - De-identified subject ID (phv00202671.v1.p1)
SUBJECT_ID - Subject ID (phv00202666.v1.p1)
SUBJECT_ID - Subject ID (phv00202662.v1.p1)
SUBJECT_SOURCE - Source repository where subjects originate (phv00202664.v1.p1)
Total.BED - Total biologically effective dose, combining EBRT and implant dose when both treatments were used, calculated using an (phv00202689.v1.p1)
treatment - Radiotherapy type (external beam radiotherapy, EBRT; brachytherapy) (phv00202683.v1.p1)